Development of the NMDA ion-channel blocker, aptiganel hydrochloride, as a neuroprotective agent for acute CNS injury.
McBurney
R N
RN
Cambridge NeuroScience, Inc., MA 02139, USA.
D000208:Acute Disease; D001930:Brain Injuries / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002561:Cerebrovascular Disorders / Q000188:drug therapy; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000737:chemistry / Q000494:pharmacology*; D015600:Glasgow Coma Scale; D006146:Guanidines / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D016202:N-Methylaspartate / Q000037:antagonists & inhibitors*; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology*; D012016:Reference Values; D013119:Spinal Cord Injuries / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology
D015507:Drugs, Investigational; D006146:Guanidines; D018696:Neuroprotective Agents; C079779:aptiganel; D016202:N-Methylaspartate